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Expansion of Human Regulatory T-Cells From Patients
With Type 1 Diabetes
Amy L. Putnam,1 Todd M. Brusko,1 Michael R. Lee,1 Weihong Liu,1 Gregory L. Szot,1
Taumoha Ghosh,1 Mark A. Atkinson,2 and Jeffrey A. Bluestone1
OBJECTIVE—Regulatory T-cells (Tregs) have catalyzed the
field of immune regulation. However, translating Treg-based
therapies from animal models of autoimmunity to human clinical
trials requires robust methods for the isolation and expansion of
these cells—a need forming the basis for these studies.
RESEARCH DESIGN AND METHODS—Tregs from recent-
onset type 1 diabetic patients and healthy control subjects were
isolated by fluorescence-activated cell sorting and compared for
their capacity to expand in vitro in response to anti-CD3–anti-
CD28–coated microbeads and IL-2. Expanded cells were exam-
ined for suppressive function, lineage markers and FOXP3, and
cytokine production.
RESULTS—Both CD4CD127lo/ and CD4CD127lo/CD25 T-
cells could be expanded and used as Tregs. However, expansion of
CD4CD127lo/ cells required the addition of rapamycin to main-
tain lineage purity. In contrast, expansion of CD4CD127lo/CD25
T-cells, especially the CD45RA subset, resulted in high yield,
functional Tregs that maintained higher FOXP3 expression in the
absence of rapamycin. Tregs from type 1 diabetic patients and
control subjects expanded similarly and were equally capable of
suppressing T-cell proliferation. Regulatory cytokines were pro-
duced by Tregs after culture; however, a portion of FOXP3 cells
were capable of producing interferon (IFN)- after reactivation.
IFN- production was observed from both CD45RO and
CD45RA Treg populations.
CONCLUSIONS—The results support the feasibility of isolating
Tregs for in vitro expansion. Based on expansion capacity, FOXP3
stability, and functional properties, the CD4CD127lo/CD25 T-
cells represent a viable cell population for cellular therapy in this
autoimmune disease. Diabetes 58:652–662, 2009
Multiple defects within the innate and adaptiveimmune systems are associated with the de-velopment of type 1 diabetes (1). Collectively,these defects lead to an imbalance in immune
regulation that facilitates the expansion of pathogenic
autoreactive T- and B-cells, resulting in the eventual
destruction of insulin-producing -cells (2,3). In recent
years, appreciation has grown for the critical role Tregs
play in maintaining immune tolerance (2). Studies in
animal models and humans indicate a failure of Tregs to
develop or function results in the development of systemic
autoimmune disease (4,5). This is most apparent in hu-
mans with mutations in the gene encoding the transcrip-
tion factor FOXP3, which is necessary for the proper
development and function of Tregs (6). Additionally, trans-
fer of excess Tregs into diabetes-susceptible NOD mice
has been shown to prevent and even reverse disease (7).
With this, the field of immune therapy has undergone a
paradigm shift in recent years favoring treatments that
elicit dominant immune regulation by Tregs over those
that result in broad immunosuppression (8). One such
therapy involving treatment with the anti-CD3 antibody
has recently shown some efficacy in preserving -cell
function in patients with type 1 diabetes, partly by increas-
ing immune regulation via Tregs (9). Another seemingly
paradoxical approach is the use of low doses of interleu-
kin (IL)-2, especially in conjunction with rapamycin, to
enhance Treg survival and expansion (10,11). Autologous
therapies using Tregs represent an attractive therapeutic
approach (12); however, these therapies are limited by the
relatively low frequency of Tregs in circulation (compris-
ing roughly 5–7% of CD4 T-cells) (13), and it remains
unclear whether a sufficient number of “pure” Tregs can be
generated from these patients. One means of overcoming
the limiting cell numbers is by isolating and expanding
autologous Tregs before adoptive cell transfer. Whereas
this procedure has been widely used for effector T-cells in
HIV and cancer immunotherapy, an application using
Tregs for the treatment of autoimmune diseases and
graft-versus-host disease has only begun to be explored
(14). Inherent to this application is the requirement for
robust methods to isolate sufficiently pure populations
from patients that will not result in the outgrowth of
potentially pathogenic T-cells.
In this study described herein, we present two protocols
for isolating and expanding adult human Tregs from
patients with recent-onset type 1 diabetes. Our procedures
are based on a clinically relevant fluorescence-activated
cell sorting (FACS)-based isolation and in vitro expansion
procedure that uses our recently described CD127 marker
(IL-7 receptor -chain) in combination with CD25 (IL-2
receptor -chain) or rapamycin (15). Moreover, we char-
acterize the phenotypic and functional properties of these
cells after in vitro expansion and suggest that these
approaches lead to selective expansion of cells with
immunosuppressive properties.
RESEARCH DESIGN AND METHODS
Patient population. Tregs were isolated from nine adult individuals with
recent-onset type 1 diabetes (six men/three women; mean age 26.0  9.7
years, range 17–40, with a mean disease duration of 7 months, range 20 days
to 11 months) at the time of blood draw (i.e.,12 months from diagnosis) and
three nondiabetic healthy control subjects (one man/two women; mean age
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33  1.5 years, range 31–34) from the general population. All patients with
type 1 diabetes were diagnosed according to American Diabetes Association
criteria (16). Control subjects lacked any autoimmune disorders or related
probands with type 1 diabetes. Informed consent was obtained in accordance
with approved policies and procedures.
Sample processing. Fresh peripheral blood was collected in sodium hepa-
rinized vacutainer tubes (Becton Dickinson [BD], Franklin Lakes, NJ) and
processed within 24 h for isolation of peripheral blood mononuclear cells
(PBMCs). Complete cell isolation and culture guidelines including cell num-
bers, volumes, and respective culture flasks are outlined in detail in the
Supplemental Methods section (available in an online-only appendix at
http://dx.doi.org/10.2337/db08-1168).
Isolation of Tregs. Tregs were isolated on a BD FACSAria II high-speed cell
sorter (BD Biosciences, San Jose, CA) with the following antibodies: CD4-
PerCP (SK3), CD127-PE (hIL-7R-M21), CD25-APC (2A3), CD45RA-PE.Cy7
(L48), and CD45RO-PE.Cy5 (UCHL1). CD4CD127lo/CD25 and CD4CD127lo/
T-cells were sorted using an aseptic technique in a cGMP-level clean room
facility, and the sorted populations were collected into 3 ml X-VIVO 15 media
(Lonza, Walkersville, MD) containing 10% human heat-inactivated pooled AB
serum (Valley Biomedical, Winchester, VA). Treg populations were analyzed
for purity post-sort and determined to be 97.96  1.6%, range 95–100%, for
CD4CD127lo/CD25 T-cells and 98.76  1.17%, range 96.2–100%, for
CD4CD127lo/ T-cells.
In vitro expansion procedure. FACS isolated cells were plated at 2.5  105
Tregs per well in a 24-well plate (Costar, Cambridge, MA) and activated with
anti-CD3/anti-CD28–coated microbeads (Invitrogen, Carlsbad, CA) at a 1:1
bead-to-cell ratio. CD4CD127lo/ cells received rapamycin (100 ng/ml; Wyeth,
Madison, NJ) through day 7 of culture (assuming consumption). At day 2, the
culture volume was doubled and IL-2 was added (300 units/ml, Proleukin;
Chiron Therapeutics, Emeryville, CA). Cells were resuspended and fresh
media and IL-2 were added at days 2, 5, 7, 9, and 12 assuming consumption. On
day 9, cells were restimulated with fresh anti-CD3/anti-CD28–coated beads at
a 1:1 ratio.
Phenotypic analysis of expanded populations. Freshly expanded cells
were evaluated for continued expression of CD4, CD25, CD127, and FOXP3.
Alexa488-conjugated anti-FOXP3 (clone 206D) was purchased from BioLeg-
end (San Diego, CA), and intracellular staining was performed with the FOXP3
staining kit (BioLegend) according to the manufacturer’s instructions and
modified as follows: 5  105 cells were washed and fixed for 30 min at room
temperature using fixation/permeabilization buffer. Cells were washed, resus-
pended in perm buffer containing DNase I (100 units/ml; Sigma-Aldrich, St.
Louis, MO), and incubated for 30 min at room temperature, followed by two
washes in perm buffer. Cells were subsequently blocked with human IgG (5
	g/test) for 5 min and stained for surface markers along with anti-human
FOXP3-Alexa488 (5 	l/test) or isotype control. Flow cytometric data were
collected on a FACSCalibur cytometer (BD Biosciences) and analyzed with
FlowJo software (version 7.2.2; TreeStar, Ashland, OR).
In vitro suppression assays. In repeated studies, we have observed that
expanded Tregs suppress both CD4 and CD8 allogeneic and mitogen-
stimulated T-cell responses. For the purposes of this study, in vitro suppres-
sion was assessed based on their capacity to suppress the proliferation of
allogeneic CD8 responder T-cells. To compare different Treg populations
against a common responder, a normal healthy donor was apheresed and
PBMCs were cryopreserved in multiple aliquots. For the carboxyfluorescein
diacetate succinimidyl ester (CFSE)-based suppression assay, individual vials
of standard responders (containing 
5  106 cells/vial) were thawed, CFSE
labeled (Invitrogen; 0.3 	mol/l), and plated in the presence of unlabeled Tregs
at various ratios of Treg to responder cells. Cells were stimulated with 2 	g/ml
soluble anti-CD3 (Hit3a) and anti-CD28 (28.2; BD PharMingen). Cultures were
incubated for 4 days at 37°C in a 5% CO2 incubator. At day 4, cells were
harvested, pooled for each condition, and stained with CD8-APC (BD Bio-
sciences) to assess proliferation. Cells were gated by forward scatter (FSC)/
side scatter (SSC) and CD8 responders to discriminate them from Tregs. A
CFSE histogram of unstimulated responder cells defined the parent popula-
tion, and proliferation of activated responders was determined by calculation
of precursor frequency (pf) using ModFit LT software (Verity Software House,
v3.0; Topsham ME). In some instances, proliferation was also determined by
the incorporation of 3H-thymidine by pulsing cultures with 1 	Ci for the final
16 h of culture. Plates were harvested on a Packard FilterMate Harvester and
read on a Packard TopCount Scintillation and Luminescence Counter (Perkin
Elmer, Waltham, MA). For both assays, percent suppression was calculated as
previously described (17).
In vitro suppression assays were conducted in RPMI-1640 (Mediatech,
Manassas, VA) supplemented with 5 mmol/l HEPES, 2 mmol/l L-glutamine,
penicillin/streptomycin (50 	g/ml each) (Invitrogen), 50 	mol/l 2-mercapto-
ethanol (Sigma), 5 mmol/l nonessential amino acids, 5 mmol/l sodium pyru-
vate (Mediatech), and 2.5% human serum. Cultures were maintained in 200-	l
volumes in U-bottom 96-well plates (Costar, Cambridge, MA) incubated at
37°C and 5% CO2. Neutralizing antibodies to transforming growth factor
(TGF)- or IL-10 were obtained from R&D Systems (Minneapolis, MN) and
control goat IgG (Jackson ImmunoResearch, West Grove, PA).
Cytokine analysis. Tregs were assessed for cytokine production at day 14 of
culture via intracellular staining and analyses of culture supernatants. For
analysis of cytokines in supernatants, fresh supernatant was collected directly
from expansion cultures or from a subset of cells (1  106 cells) reactivated
in fresh media with beads (1:1) or phorbol myristate acetate (PMA) (10 ng/ml)
and ionomycin (500 ng/ml) (Sigma) for an additional 5 h at 37°C.
Cytokine determinations were conducted in a multiplex format using either
the Luminex platform with the cytokine multiplex kit (analytes interferon
[IFN]-, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, MIP-1, RANTES,
sCD40L, sIL-2R, and TNF-; Millipore, Bellerica, MA) or with the Cytometric
Bead Array (human Th1/Th2 cytokine kit II; BD PharMingen). TGF- concen-
trations, determined using the Quantikine Human TGF- ELISA kit (R&D
Systems), showed that the human serum used for these studies contained
18.08 ng/ml TGF-1. Intracellular cytokines were stained directly from cul-
tures at day 14 or after 5 h of reactivation with beads or PMA/ionomycin.
Intracellular cytokine staining was conducted with FOXP3 staining using the
manufacturer kit reagents from BioLegend as previously described along with
the anti-human cytokine antibodies IFN- phycoerythrin and IL-10 allophyco-
cyanin (BD PharMingen).
Statistics and methods of analysis. Data analyses used GraphPad Prizm
4.00 software (GraphPad, San Diego, CA), and values at P 0.05 were deemed
significant. Cytokine concentrations were determined using SOFTmax® PRO
software (Molecular Devices, Sunnyvale, CA) with four-parameter data anal-
ysis. Spearman’s correlation analyses were used to compare Treg expansion
to the subject’s age, and Student’s paired t tests were used to compare
responses for CD4CD127lo/ and CD4CD127lo/CD25 T-cells.
RESULTS
Isolation and characterization of human Tregs. In an
effort to develop an optimal protocol for expanding Tregs
for therapeutic use, we examined two different strategies
based on the use of a limited number of antibodies and
techniques that can be adapted to cGMP-level standard
operating procedures. As previously observed, the major-
ity of FOXP3 T-cells in peripheral blood are CD127
negative to low (Fig. 1A, left plot). Moreover, CD25 expres-
sion was positively correlated with FOXP3 expression
(Fig. 1A, right plot, and Supplemental Fig. 1 and anima-
tions). CD4 T-cells display varying levels of FOXP3 based
on a combination of the markers, with the highest levels of
FOXP3 cells being within the CD4CD127lo/CD25 sub-
set (Fig. 1B, typically 95% FOXP3). Therefore, our
primary strategy consisted of isolating the highly FOXP3-
expressing CD4CD127lo/CD25 (15) cell population.
Likewise, inclusion of the CD127 marker improves the
overall yield of FOXP3 T-cells by allowing collection of
CD25lo and CD25Intermediate cells that would otherwise be
lost if cells were sorted based on being solely CD4CD25hi,
as has been reported to contain cells enriched for FOXP3
suppressors (18). As a second strategy, we examined the
ability to expand all the CD4CD127lo/ T-cells irrespective
of CD25 expression, since this population represented a
larger initial cell number, which we previously showed
had suppressive activity when isolated directly from pe-
ripheral blood (15). The selective immunosuppressive
agent, rapamycin, was used in these cultures to prevent
outgrowth of contaminating nonregulatory cells (19). It is
important to note that, in both procedures, the exclusion
of CD127hi expressing cells made it possible to isolate
Tregs devoid of memory effector T-cells (Teff) (15,20).
Importantly, because the ability to broaden the cell sur-
face phenotype to cells expressing lower levels of CD25
allowed for the isolation of the most Tregs from patients
with type 1 diabetes, a patient population where CD25 has
been suggested to be a susceptibility gene and where there
A.L. PUTNAM AND ASSOCIATES
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has been a suggestion that the CD4CD25hi population
may be defective (21–23).
We next sought to develop a method to consistently and
reproducibly isolate these cells for in vitro expansion.
Procedures currently approved for clinical applications
using isolated human cells rely on sorting cells using
antibody-coated microbeads in an automated magnetic
separation device. Whereas there are advantages to this
system for isolating bulk populations using defined mark-
ers such as CD4, microbead-based sorting is limited when
multiple markers are needed or when markers exhibit
broad expression patterns. To overcome these limitations,
we sorted Tregs in a FACS-based approach. Our sorting
scheme to isolate CD4CD127lo/CD25 and CD4
CD127lo/ T-cells is shown in Fig. 2A. Representative
examples for each population with post-sort FOXP3 anal-
ysis are shown in Fig. 2B.
In vitro expansion of Tregs. Given the relatively low
circulating frequency of Tregs, most applications will
require in vitro expansion to impact the effective Treg to
Teff cell ratio (12). We previously showed in mouse
models (24) that overcoming the anergic state of Tregs
for the purposes of expansion requires strong TCR and
costimulatory signals in the presence of high-dose IL-2
(25). Thus, our approach took advantage of anti-CD3/
anti-CD28–coated beads and IL-2 as outlined in Fig. 3A
(detailed conditions included in Supplemental Methods
Section).
As previously discussed, the original isolation proce-
dure greatly influences the subsequent degree of in vitro
expansion required. However, this factor is offset by the
observation that less-pure starting populations require
more stringent growth conditions to ensure Treg expan-
sion over the outgrowth of Teff cells (19). One means to
accomplish selective growth of Tregs is through the use of
rapamycin (16). However, preliminary studies suggested
that the addition of this mTOR inhibitor delayed the
expansion potential of T-cells (Supplemental Fig. 2). Thus,
CD4CD127lo/ T-cells were grown in the presence of
rapamycin for only the first 7 days of culture. In this way,
we were able to obtain a mean expansion of 1,248 
930-fold, median 1,347, range 117–2,886, over a 14-day
period. The highly purified CD4CD127lo/CD25 T-cell
population, grown without rapamycin, expanded to com-
parable levels (mean 1,532  938.7, median 1,548, range
340–3,171-fold). Representative expansion curves for both
cell populations are shown in Fig. 3B, and expansion data
for all subjects analyzed are graphed in Fig. 3C.
One of the surprising observations resulting from these
studies was the degree of heterogeneity in expansion from
one individual to the next. We hypothesized that some of
the variability might be explained by the age of the donor.
It has been previously reported that aging is associated
with a shift in T-cell phenotype from a predominantly
naïve T-cell subset (CD45RA) to a memory (CD45RO)
T-cell phenotype (20). This shift has also been associated
with increased cellular senescence, partially resulting
from the shortening of telomeric DNA (26,27). Naïve
T-cells have been reported to contain longer telomeres
compared with antigen-experienced cells (28). In line with
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FIG. 1. CD4, CD25, and CD127 identify FOXP3 Tregs in human peripheral blood. A: CD127 expression inversely correlates with FOXP3
expression in freshly isolated human peripheral blood CD4 T-cells (left plot), whereas CD25 expression is positively correlated with FOXP3
expression (right plot). B: Using the combination of these markers, the highest purity of FOXP3 T-cells is found within the CD4CD127lo/
CD25 T-cell fraction (
95%). One representative sample is shown. (A three-dimensional plot and animated rotations showing Treg and Teff
staining are shown in Supplemental Fig. 1 and supplemental videos.)
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this notion, we observed a negative correlation between
subject age and fold expansion for CD4CD127lo/CD25
T-cells (Fig. 4A; r  0.77, P  0.0033). To determine if
this observation could be influenced by the relative pro-
portion of memory and naïve cells, CD4CD127lo/CD25
T-cells were additionally sorted based on CD45RA versus
CD45RO expression and expanded according to our
standard protocol. We observed that CD45RA Tregs
expanded better than their CD45RO counterparts (Fig.
4B, mean fold expansion 317.0 294.5 for CD45RA Tregs
vs. 59.7  43.1-fold for CD45RO, n  3). This increased
expansion potential was accompanied by increased purity
(based on FOXP3 expression) and suppressive properties
of expanded CD45RA Tregs compared with CD45RO
Tregs. Representative examples of FOXP3 expression and
in vitro suppression are shown in Fig. 4C and D, respec-
tively. Thus, we conclude that expansion can be achieved
with either CD4CD127lo/CD25 or CD4CD127lo/ T-
cells (in the presence of rapamycin). However, the major-
ity of the expansion results from the CD45RA T-cell
subset, which has implications for using expanded Treg
cell therapy in older individuals.
Stability of a regulatory T-cell phenotype after in
vitro expansion. Given the comparable expansion poten-
tial of CD4CD127lo/ and CD4CD127lo/CD25 T-cells,
we next sought to assess the functional properties of these
cells after expansion. As the prototypical marker for Tregs,
FOXP3 expression was analyzed by FACS along with CD4,
CD25, and CD127 at the 7- and 14-day time points of
culture (Fig. 5A, upper panels, for CD4CD127lo/CD25
T-cells, and Fig. 5B, lower panels, for CD4CD127lo/
T-cells). As predicted based on the initial higher percent-
age of FOXP3 within the CD4CD127lo/CD25 subset, we
observed a higher percentage of FOXP3 T-cells in the
expanded CD4CD127lo/CD25 T-cells at day 7 (Fig. 5C,
left graph, mean 91.1 5.4%, median 92.4, range 79.1–97.8)
compared with that obtained with CD4CD127lo/ T-cells
(69.6  10.2, median 69.1, range 55.1–84.7). This trend
continued at day 14 (Fig. 5C, right graph, 75.9  10.7,
median 76.4, range 60.8–94.3, for CD4CD127lo/CD25
T-cells and 53.4  18.2, median 52.8, range 30.2–86.0, for
CD4CD127lo/ T-cells).
Relative FOXP3 expression within individual cells was
upregulated in expanded cultures upon reactivation with
either beads or PMA and ionomycin (Supplemental Fig. 3).
These observations are in line with other reports suggest-
ing that activated expanded Tregs are more potent sup-
pressors (29), along with reports suggesting that
costimulatory signals (such as those provided by CD28
and IL-2) may function to upregulate FOXP3 (30,31).
Interestingly, Tregs cultured in the presence of brefeldin-A
suppressed the FOXP3 increase and in fact led to down-
regulation of surface CD25 and FOXP3 (data not shown),
suggesting that the affect of T-cell stimulation may be due
to both transcriptional and translational effects. In addi-
tion to FOXP3, expanded Tregs expressed high levels of
markers putatively associated with terminally differenti-
ated Tregs including HLA-DR, CTLA-4 (BD PharMingen),
and TGF-1–LAP (R&D Systems) (Supplemental Fig. 4).
We next tested the capacity of expanded Tregs to
suppress proliferation of CD8 T-cells using a standard-
ized allogeneic responder T-cell population stimulated
with anti-CD3 and anti-CD28 (Fig. 6A). Despite more
variable and often reduced numbers of FOXP3 cells in
the expanded CD4CD127lo/ T-cell population, these
cells suppressed responder T-cell proliferation to a similar
degree on a per cell basis when compared with
CD4CD127lo/CD25 T-cells (Fig. 6B, P  NS for all
ratios Treg:Tresponders). Likewise, for all ratios of Treg:
Tresponders, no significant difference in suppressive ca-
pacity was observed for type 1 diabetic patient Tregs
compared with normal healthy control Tregs. The mecha-
nism of suppression of expanded Tregs was determined to
be independent of IL-10 or TGF-, since the addition of
neutralizing antibodies to these cytokines during the in
vitro suppression assay failed to abrogate suppression
(data not shown).
Expression of cytokines by expanded regulatory T-
cells. Fresh Tregs are generally noted for their lack of
cytokine production when directly examined after isola-
tion from peripheral blood. In fact, one of the clear
disconnects is the relative lack of evidence that cytokines
are involved in in vitro suppression by Treg, whereas
multiple in vivo studies in rodent models suggest a clear
role for IL-10 and TGF- in Treg function (32,33). There-
fore, we analyzed the ability of the expanded Treg popu-
lations to produce cytokines that might either enhance or
abrogate Treg function in vivo. In addition, the analyses of
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FIG. 2. Gating strategy and FOXP3 analysis of freshly isolated CD4
CD127lo/ and CD4CD127lo/CD25 T-cells. A: Tregs were isolated
from peripheral blood through a FACS-based sorting procedure. The
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cytokine production might also identify contaminating
effector T-cells that might be a potential concern with
adoptive cell therapy in autoimmune patients. Analyses of
culture supernatants of individual expanded T-cell popu-
lations suggested that, in general, there was very low
production of IFN- with relatively high expression of
IL-10, when compared with effector T-cells (CD4
CD127) expanded under the same conditions (Fig. 7). A
portion of expanded Tregs were capable of producing
cytokines after anti-CD3/anti-CD28–coated bead or PMA/
ionomycin reactivation (Fig. 7A for CD4CD127lo/CD25
T-cells and Fig. 7B for CD4CD127lo/ T-cells; see also
data from a panel of 14 cytokines and soluble receptors in
Supplemental Table 1). It is generally accepted that IFN-
represents a TH1-type effector cytokine (34), whereas IL-10
has been ascribed to exhibit multiple immunoregulatory
functions (35). Therefore, we assessed the ratio of IL-10 to
IFN- production in supernatants from stimulated
CD4CD127lo/ and CD4CD127lo/CD25 T-cell popula-
tions (Fig. 7C). This analysis suggests that stimulated
CD4CD127lo/CD25 Tregs produce proportionately
more IL-10 to IFN- compared with CD4CD127lo/ T-cells
(P  0.0014).
Next, we analyzed the production of the key cytokines
on a per cell basis using a combination of intracellular
cytokine and FOXP3 staining on expanded Treg cultures.
As was previously observed in supernatants, the produc-
tion of IFN- followed the general trend of cytokine
production from the different cell populations as follows
(Fig. 8; CD4CD127 Teff  Tregs) and likewise for
stimulation signal strength (Fig. 8; PMA/ionomycin 
anti-CD3/anti-CD28 beads  fresh from culture). Specifi-
cally, we observed a significant portion of the FOXP3
T-cells produced IFN- after reactivation with PMA/iono-
mycin (median 11.6%, range 3.25–15.88, n  6). IFN-
production within the FOXP3 cells was comparable in all
conditions between freshly isolated and expanded cells,
suggesting this does not result solely from in vitro expan-
sion (Supplemental Table 2). It remained possible that the
IFN-–producing T-cells were contaminating Teff cells,
which can express low levels of FOXP3. Therefore, cells
were split into memory (CD45RO) and naïve (CD45RA)
T-cell fractions before expansion and cytokine analyses.
Importantly, IFN-–producing cells were observed in the
CD45RA Treg subset (albeit lower than observed from the
CD45RO subset), suggesting this bona fide Treg popula-
tion contains cells capable of producing cytokines. In fact,
we observed that Tregs isolated and expanded from
umbilical cord blood (presumably a functionally naïve
repertoire) also produce IFN- (see Supplemental Fig. 5),
suggesting human FOXP3 T-cells are capable of produc-
ing cytokines after various activation conditions.
DISCUSSION
One potential path for an effective therapy to reverse type
1 diabetes would involve the restoration of homeostasis
within the immune system normally controlled by Tregs.
Compelling evidence exists from the NOD mouse that
transfer of in vitro expanded Tregs can overcome intrinsic
defects and restore tolerance in type 1 diabetes (12). The
therapeutic benefits of restoring tolerance early in type 1
diabetes would likely result in the preservation of endog-
enous -cell mass and subsequent reduction in complica-
tions resulting from hyperglycemia. Treg-based cell
therapies pose several advantages over cell-depleting reg-
imens and bone marrow transplantation protocols, in that
they are unlikely to compromise host immune responses
to foreign pathogens.
In this study, we demonstrated that functional Tregs can
be isolated from patients with type 1 diabetes and ex-
panded in vitro to therapeutically relevant levels. Most
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importantly, we demonstrated that we could attain on
average 1,500-fold expansion of the highly purified
CD4CD127lo/CD25 T-cell population in a 14-day cul-
ture period using methods that can be adapted to cGMP
procedures. Moreover, cells from both type 1 diabetic
patients and healthy volunteers grown under these condi-
tions retain the hallmark characteristics of freshly isolated
Tregs (i.e., they are anergic after culture, suppressive, and
continue to express high levels of the transcription factor
FOXP3).
Several previous studies have reported methods for
isolating and expanding natural FOXP3-expressing Tregs
for therapeutic applications from healthy individuals
(36,37). However, these alternative approaches can fall
short of meeting clinical needs in terms of the initial cell
yield, the feasibility of adapting protocols to cGMP levels,
or the purity and stability of the expanded cell populations
post-transfer, especially in patients with autoimmune dis-
eases as highlighted below. We sought to address these
concerns and meet these important therapeutic criteria.
The use of cellular therapies in individuals with type 1
diabetes raises concerns regarding the subsequent func-
tion of cells in patients presumably carrying a genetic
predisposition toward autoimmunity. There is growing
evidence from genetic studies in the NOD mouse and
humans implicating pathways likely to influence Treg
frequency and/or function. These genes include, but are
not limited to, the IL-2 signaling axis (Il2 in the NOD
mouse and CD25 in humans), the T-cell signaling molecule
LYP (protein tyrosine phosphatase [PTPN22]), and the
negative T-cell regulator cytotoxic T-lymphocyte antigen-4
(CTLA-4) (38–40). Susceptibility alleles in these pathways
may confer deficient immune activation and subsequent
control by Tregs (10,19). One means to overcome this
inherent defect may be the use of matched allogeneic
cells, such as that recently reported for bone marrow
transplantation in a model of autoimmune arthritis (41).
Although this approach may be advantageous from an
immunoregulatory standpoint, the safety and efficacy pro-
file of such an approach in patients with type 1 diabetes
remains unknown. These questions require initial trials
with autologous cells with the expectation that in vitro
activation and IL-2 exposure will augment the functional
profile of Tregs (29).
A major concern when proposing to expand Tregs from
type 1 diabetic patients or other autoimmune subjects is
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the potential for outgrowth of activated Teff cells. Central
to addressing this concern is our inclusion of the CD127
marker, which enables us to discriminate between acti-
vated Teff cells and bona fide Tregs (15). As an additional
constraint, we chose to isolate Tregs through a stringent
FACS-based sorting approach. Using these parameters, we
were able to show expansion of functional CD4CD127lo/
T-cells grown in the presence of rapamycin as well as
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highly purified CD4CD127lo/CD25 T-cells. Surprisingly,
both of these populations suppressed equally well during
the in vitro suppression assay despite decreased numbers
of FOXP3 cells present in CD4CD127lo/ T-cells. This
may result from an unknown suppressive property of
CD127lo/ T-cells, or alternatively, from the differentiation
of FOXP3 T-cells into IL-10– or TGF-–producing adap-
tive Tregs. This process has previously been reported to
occur through exposure of conventional T-cells to Tregs in
vitro or in vivo in a process commonly referred to as
education (42–44).
Despite the similar suppressive properties of
CD4CD127lo/ T-cells, we believe CD4CD127lo/CD25
T-cells represent the optimal polyclonal Treg population
for our proposed phase I clinical trial. This conclusion is
based on the highly enriched nature of the starting popu-
lation and the ability to expand these cells to high purity
without rapamycin. While rapamycin does selectively in-
hibit Teff outgrowth in vitro, there is some concern that
these activated cells could expand after in vivo transfer in
the absence of the drug. Therefore, when considering the
optimal cell population for cellular therapies, based on the
parameters of stability, FOXP3 expression, and in vitro
expansion potential, we have concluded that CD4
CD127lo/CD25 T-cells represent the optimal population.
Despite these promising results, several key questions
still remain regarding Treg cell therapy. Little is known
about how long expanded Tregs will persist upon transfer,
where they track, or whether they retain their suppressive
phenotype in vivo. To begin to address the issue of cell
stability, we assessed the cytokine production profiles of
expanded Tregs. Surprisingly, analyses of intracellular
cytokines from expanded human Tregs indicate FOXP3
expression, and production of IFN- is not mutually ex-
clusive. In fact, we noted that several other cytokines
typically associated with effector functions could also be
co-expressed with FOXP3 including IL-17 and TNF-,
whereas IL-2 and IL-4 appeared more restricted to the
FOXP3 T-cell fraction (data not shown). The in vivo
physiological significance of these observations in re-
sponse to super-physiological stimuli is not clear, nor is
the notion that these responses are detrimental. Neverthe-
less, these questions regarding the stability of Tregs are of
great importance, and we are continuing to investigate
these issues through studies with humanized mice (45), as
well as FoxP3 reporter mice that can discriminate cells
that are currently expressing FoxP3, or have expressed it
at any point in development (46).
Animal model data support the use of Tregs to halt type
1 diabetes progression and suggest transfer of Tregs may
lead to reversal of ongoing disease (7,24,47). With that
said, this may be challenging in subjects after the pro-
cesses of epitope spreading and memory T-cell expansion.
Here we propose the use of polyclonal Tregs as a neces-
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sary advancement in the use of Tregs for the treatment of
type 1 diabetes. However, we acknowledge that overcom-
ing the autoimmune attack in type 1 diabetes in the future
may require even more challenging approaches involving
combination therapies or the use of antigen-specific Tregs.
To begin to address these issues, we are currently devel-
oping protocols for the generation of antigen-specific
Tregs capable of recognizing diabetes autoantigens
through the use of viral TCR- and TCR- gene transfer
into CD4CD127lo/CD25 T-cells.
In conclusion, our data indicate functional Tregs can be
isolated and expanded from recent-onset type 1 diabetic
patients. These Tregs can be expanded in vitro to 1,500-
fold in a 2-week period using cGMP-level materials and
procedures. These cells retain potent suppressive function
and FOXP3 expression without the need for rapamycin.
This study outlines important tools and principles for
translating Treg therapies into clinical treatments for
patients with type 1 diabetes and other autoimmune
disorders.
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